OsteoBites Welcomes Bhuvana Setty, MD

OsteoBites Welcomes Bhuvana Setty, MD

Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy combined w/ Gemcitabine & Docetaxel

By MIB Agents

Date and time

Thursday, July 25 · 12 - 1pm PDT

Location

Online

About this event

  • 1 hour

Osteosarcoma Webinar Series: Dr. Bhuvana Setty will join us on OsteoBites to discuss the role of adapting the immune system in the fight against cancer. She will discuss the ongoing study utilizing natural killer (NK) cells in combination with a chemotherapy backbone for patients with relapse osteosarcoma and other sarcomas. She will discuss preclinical data supporting the utilization of NK cells in this patient population and discuss the goals of the clinical trial.


Bhuvana Setty, MD, is a Pediatric Hematologist/Oncologist at Nationwide Children's Hospital. Her clinical interests include treating pediatric and young adult patients with bone and soft tissue sarcomas, and patients with vascular anomalies. She is the Director of the Clinical Sarcoma Team. She is the Site Principal investigator for the Sunshine Project supported by the National Pediatric Cancer Foundation and serves as the lead for the Ewing sarcoma Task Force at the Sunshine Project. In addition, she is the Site Principal Investigator for The Sunshine Project, an early phase clinical trial consortium and CaNVAS, the Consortium of iNvestigators for Vascular Anomalies. Her research interests include developing translational and therapeutic clinical trials with novel agents for patients with aggressive bone and soft tissue sarcomas. She leads as National PI for the TINKS trial as well as the upcoming metastatic Ewing sarcoma trial at the Children's Oncology Group.


After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

Organized by